tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2021 Nov 6;9(2)
fab566.
doi: 10.1093/ofid/ofab566. eCollection 2022 Feb.
Coronavirus Disease 2019-Associated Mucormycosis in France: A Rare but Deadly Complication
François Danion[SUP] 1 2 [/SUP], Valérie Letscher-Bru[SUP] 3 [/SUP], Juliette Guitard[SUP] 4 [/SUP], Karine Sitbon[SUP] 5 [/SUP], Sarah Dellière[SUP] 6 [/SUP], Adela Angoulvant[SUP] 7 8 [/SUP], Guillaume Desoubeaux[SUP] 9 [/SUP], Francoise Botterel[SUP] 10 [/SUP], Anne-Pauline Bellanger[SUP] 11 [/SUP], Gilles Gargala[SUP] 12 [/SUP], Fabrice Uhel[SUP] 13 [/SUP], Marie-Elisabeth Bougnoux[SUP] 14 [/SUP], Victor Gerber[SUP] 15 [/SUP], Justin Michel[SUP] 16 [/SUP], Marjorie Cornu[SUP] 17 18 [/SUP], Stéphane Bretagne[SUP] 5 6 [/SUP], Fanny Lanternier[SUP] 5 19 [/SUP], COVID-Mucor study group
Collaborators, Affiliations
Abstract
We studied COVID-19 associated mucormycosis based on 17 cases reported nationwide and assessed the differences with India. They differed by frequencies of diabetes mellitus (47% in France versus up to 95% in India), hematological malignancies (35% versus 1%), anatomical sites (12% versus >80% rhino-orbito-cerebral) and prognosis (88% mortality versus <50%).
Keywords: CAM; CAPA; COVID-19; mucormycosis.
. 2021 Nov 6;9(2)
fab566.doi: 10.1093/ofid/ofab566. eCollection 2022 Feb.
Coronavirus Disease 2019-Associated Mucormycosis in France: A Rare but Deadly Complication
François Danion[SUP] 1 2 [/SUP], Valérie Letscher-Bru[SUP] 3 [/SUP], Juliette Guitard[SUP] 4 [/SUP], Karine Sitbon[SUP] 5 [/SUP], Sarah Dellière[SUP] 6 [/SUP], Adela Angoulvant[SUP] 7 8 [/SUP], Guillaume Desoubeaux[SUP] 9 [/SUP], Francoise Botterel[SUP] 10 [/SUP], Anne-Pauline Bellanger[SUP] 11 [/SUP], Gilles Gargala[SUP] 12 [/SUP], Fabrice Uhel[SUP] 13 [/SUP], Marie-Elisabeth Bougnoux[SUP] 14 [/SUP], Victor Gerber[SUP] 15 [/SUP], Justin Michel[SUP] 16 [/SUP], Marjorie Cornu[SUP] 17 18 [/SUP], Stéphane Bretagne[SUP] 5 6 [/SUP], Fanny Lanternier[SUP] 5 19 [/SUP], COVID-Mucor study group
Collaborators, Affiliations
- PMID: 35071681
- PMCID: PMC8773954
- DOI: 10.1093/ofid/ofab566
Abstract
We studied COVID-19 associated mucormycosis based on 17 cases reported nationwide and assessed the differences with India. They differed by frequencies of diabetes mellitus (47% in France versus up to 95% in India), hematological malignancies (35% versus 1%), anatomical sites (12% versus >80% rhino-orbito-cerebral) and prognosis (88% mortality versus <50%).
Keywords: CAM; CAPA; COVID-19; mucormycosis.